SRSF2 and acute myeloid leukemia: This is in line with our previous data indicating that patients with secondary AML only had adverse outcomes after HSCT when ELN2017 adverse-risk genetics are present [27], or that SRSF2 mutations do not associate with adverse outcomes after allogeneic HSCT [28].